ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

16,783Medicare Part D Prescriptions Filled, Including Refills

Rank: 5 out of 1019

$785K Total Retail Price of All Prescriptions

Rank: 19 out of 1019

1,228 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
47% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

0% of this provider’s 13,798 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

14 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
CARVEDILOL 1,644 1,414 10 1 3
ISOSORBIDE MONONITRATE ER 1,356 1,022 2 12
SIMVASTATIN 1,235 1,022 3 5
LISINOPRIL 1,002 836 4 2
METOPROLOL SUCCINATE 969 725 5 1
AMLODIPINE BESYLATE 643 551 6 4
FUROSEMIDE 611 526 7 6
CLOPIDOGREL 507 416 8 7
CRESTOR 462 391 9 13
NIASPAN 435 348 10 33
WARFARIN SODIUM 406 336 11 9
RAMIPRIL 402 355 12 21
PRAVASTATIN SODIUM 369 311 13 16
POTASSIUM CHLORIDE 368 312 14 15
ATORVASTATIN CALCIUM 350 279 15 10
PLAVIX 323 270 16 11
LOSARTAN POTASSIUM 270 253 17 17
DIGOXIN 236 186 18 14
METOPROLOL TARTRATE 207 194 19 8
NITROSTAT 187 116 20 27
TRILIPIX 156 127 21 70
SPIRONOLACTONE 151 101 22 23
ZETIA 150 134 23 30
DIOVAN 149 146 24 20
BENAZEPRIL HCL 144 126 25 69
LABETALOL HCL 140 125 26 63
CILOSTAZOL 136 107 27 45
HYDROCHLOROTHIAZIDE 133 114 28 18
ISOSORBIDE DINITRATE 125 100 29 76
AMLODIPINE BESYLATE-BENAZEPRIL 116 86 30 47
QUINAPRIL HCL 115 92 31 81
LISINOPRIL-HYDROCHLOROTHIAZIDE 109 67 32 28
HYDRALAZINE HCL 97 93 33 34
PRADAXA 96 91 34 24
LOSARTAN-HYDROCHLOROTHIAZIDE 94 86 35 31
CLONIDINE HCL 94 67 35 29
LIVALO 93 80 37 150
DILTIAZEM 24HR CD 88 61 38 48
LIPITOR 86 71 39 37
VYTORIN 84 84 40 62
FENOFIBRATE 83 59 41 58
BYSTOLIC 80 50 42 26
TRICOR 75 56 43 61
DIOVAN HCT 74 57 44 39
AMIODARONE HCL 73 60 45 22
PANTOPRAZOLE SODIUM 69 64 46 46
FAMOTIDINE 65 60 47 82
TRAMADOL HCL 60 39 48 71
BENICAR 58 53 49 72
DILTIAZEM 24HR ER 58 32 49 84
DILT-XR 57 34 51 222
EFFIENT 56 46 52 53
TORSEMIDE 55 44 53 50
TEKTURNA 53 38 54 95
DILTIAZEM ER 53 52 54 79
TRIAMTERENE-HCTZ 50 27 56 57
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.